GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
18/06/26	25.30 NT$	-0.39%	194,906
17/06/26	25.40 NT$	+1.20%	199,216
16/06/26	25.10 NT$	-2.33%	353,871
15/06/26	25.70 NT$	-4.10%	1,024,788
12/06/26	26.80 NT$	-3.42%	2,327,483

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange Other stock markets 18/06/2026			5-day change	1st Jan Change
25.30 ^TWD	-0.39%		-8.83%	-1.75%

11/06	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
14/05	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	2.85B 89.89M 78.28M 72.42M 67.84M 127M 8.48B 128M 860M 333M 4.17B 337M 330M 14.5B	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	2.63B 82.95M 72.24M 66.84M 62.6M 117M 7.82B 118M 794M 307M 3.85B 311M 305M 13.38B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	80.91%	Yield 2024 *	-	Yield 2025	-

11/06	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
14/05	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
15/04	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
24/03	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
14/03	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
09/12	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
25/11	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
14/11	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
30/10/25	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
29/10/25	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
14/08/25	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
13/06/25	GlycoNex, Inc. Announces Publication of Preclinical Study on Gnx1021, A Novel Glycan-Targeted Adc for Gastric Cancer	CI
28/05/25	GlycoNex, Inc. Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules	CI

1 day	-0.39%
1 week	-8.83%
Current month	-0.78%
1 month	-1.56%
3 months	+5.86%
6 months	+0.40%
Current year	-1.75%

GlycoNex Incorporation Stock

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news : GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Course Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	25	26.5
1 month	24.65	30
Current year	22.1	30
1 year	20.55	30
3 years	15.6	33.2
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	01/01/2019
Dih Fen Wu DFI	Director of Finance/CFO	-	01/01/2010
Yao Hua Lue IRC	Investor Relations Contact	-	12/11/2012

Director	Title	Age	Since
Kao Chung Tsai BRD	Director/Board Member	64	-
Tong Hsuan Chang CHM	Chairman	-	01/02/2001
Ling-Chun Tsai BRD	Director/Board Member	-	25/05/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	-0.39%	-8.83%	-16.91%	-17.72%	90.09M
LONZA GROUP AG	+1.44%	+1.36%	-10.88%	-12.14%	42.75B
REVOLUTION MEDICINES, INC.	+3.31%	+9.22%	+308.19%	+562.02%	34.65B
BEONE MEDICINES AG	+2.84%	+3.80%	+6.87%	+34.93%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.34%	+8.51%	-22.34%	28B
CELLTRION, INC.	-1.90%	+2.47%	+10.18%	+18.13%	24.83B
ASCENDIS PHARMA A/S	-0.14%	+7.06%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-3.13%	+52.04%	+107.47%	13.14B
EUROFINS SCIENTIFIC SE	-0.57%	-2.83%	+3.34%	+1.66%	12.61B
IONIS PHARMACEUTICALS, INC.	-0.26%	+0.41%	+100.27%	+80.69%	12.25B
Average	+0.33%	-0.06%	+51.29%	+83.63%	21.27B
Weighted average by Cap.	+0.77%	+0.91%	+64.85%	+112.17%

	2024	2025
Net sales	14.7M 464K 404K 374K 350K 656K 43.78M 662K 4.44M 1.72M 21.53M 1.74M 1.7M 74.87M	37.86M 1.2M 1.04M 963K 902K 1.69M 113M 1.71M 11.44M 4.43M 55.44M 4.49M 4.39M 193M
Net income	-230M -7.25M -6.32M -5.84M -5.47M -10.25M -684M -10.35M -69.43M -26.88M -336M -27.22M -26.64M -1.17B	-235M -7.43M -6.47M -5.98M -5.61M -10.5M -700M -10.6M -71.1M -27.53M -344M -27.88M -27.28M -1.2B
Net Debt	-442M -13.96M -12.16M -11.25M -10.54M -19.73M -1.32B -19.92M -134M -51.74M -647M -52.4M -51.27M -2.25B	-220M -6.94M -6.04M -5.59M -5.24M -9.8M -654M -9.9M -66.41M -25.71M -322M -26.04M -25.48M -1.12B